Vaccines or candidate vaccines used to prevent or treat both enterotoxigenic and enteropathogenic Escherichia coli infections.
Infections with bacteria of the species ESCHERICHIA COLI.
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.
Proteins obtained from ESCHERICHIA COLI.
A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
A verocytotoxin-producing serogroup belonging to the O subfamily of Escherichia coli which has been shown to cause severe food-borne disease. A strain from this serogroup, serotype H7, which produces SHIGA TOXINS, has been linked to human disease outbreaks resulting from contamination of foods by E. coli O157 from bovine origin.
Proteins found in any species of bacterium.
The functional hereditary units of BACTERIA.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS.
Deoxyribonucleic acid that makes up the genetic material of bacteria.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
A species of gram-negative, rod-shaped bacteria belonging to the K serogroup of ESCHERICHIA COLI. It lives as a harmless inhabitant of the human LARGE INTESTINE and is widely used in medical and GENETIC RESEARCH.
The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
Tools or devices for generating products using the synthetic or chemical conversion capacity of a biological system. They can be classical fermentors, cell culture perfusion systems, or enzyme bioreactors. For production of proteins or enzymes, recombinant microorganisms such as bacteria, mammalian cells, or insect or plant cells are usually chosen.
Agents used to prevent the formation of foam or to treat flatulence or bloat.
The application of engineering principles and methods to living organisms or biological systems.
Propylene or propene polymers. Thermoplastics that can be extruded into fibers, films or solid forms. They are used as a copolymer in plastics, especially polyethylene. The fibers are used for fabrics, filters and surgical sutures.
An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.
I'm sorry for any confusion, but "Switzerland" is a country located in Europe and not a term used in medical definitions. If you have any questions related to medical topics, I'd be happy to help answer those!
Anaerobic degradation of GLUCOSE or other organic nutrients to gain energy in the form of ATP. End products vary depending on organisms, substrates, and enzymatic pathways. Common fermentation products include ETHANOL and LACTIC ACID.
An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated.
A genus of REOVIRIDAE, causing acute gastroenteritis in BIRDS and MAMMALS, including humans. Transmission is horizontal and by environmental contamination. Seven species (Rotaviruses A thru G) are recognized.
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.
Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.
Strains of ESCHERICHIA COLI that produce or contain at least one member of either heat-labile or heat-stable ENTEROTOXINS. The organisms colonize the mucosal surface of the small intestine and elaborate their enterotoxins causing DIARRHEA. They are mainly associated with tropical and developing countries and affect susceptible travelers to those places.
An ENTEROTOXIN from VIBRIO CHOLERAE. It consists of two major protomers, the heavy (H) or A subunit and the B protomer which consists of 5 light (L) or B subunits. The catalytic A subunit is proteolytically cleaved into fragments A1 and A2. The A1 fragment is a MONO(ADP-RIBOSE) TRANSFERASE. The B protomer binds cholera toxin to intestinal epithelial cells, and facilitates the uptake of the A1 fragment. The A1 catalyzed transfer of ADP-RIBOSE to the alpha subunits of heterotrimeric G PROTEINS activates the production of CYCLIC AMP. Increased levels of cyclic AMP are thought to modulate release of fluid and electrolytes from intestinal crypt cells.

Intestinal immune responses in patients infected with enterotoxigenic Escherichia coli and in vaccinees. (1/100)

Immune responses against enterotoxigenic Escherichia coli (ETEC) were examined in Bangladeshi adults with naturally acquired disease and compared to responses in age-matched Bangladeshi volunteers who had been orally immunized with a vaccine consisting of inactivated ETEC bacteria expressing different colonization factor antigens (CFs) and the B subunit of cholera toxin. B-cell responses in duodenal biopsy samples, feces, intestinal washings, and blood were determined. Because most of the patients included in the study were infected with ETEC expressing CS5, immune responses to this CF were studied most extensively. Vaccinees and patients had comparable B-cell responses against this antigen in the duodenum: the median numbers of antibody-secreting cells (ASC) were 3,300 immunoglobulin A (IgA) ASC/10(7) mononuclear cells (MNC) in the patient group (n = 8) and 1,200 IgA ASC/10(7) MNC in the vaccinees (n = 13) (not a significant difference). Similarly, no statistically significant differences were seen in the levels of duodenal B cells directed against enterotoxin among vaccinees and patients. A comparison of the capacities of the various methods used to assess mucosal immune responses revealed a correlation between numbers of circulating B cells and antibody levels in saponin extracts of duodenal biopsy samples (r = 0.58; n = 13; P = 0.04) after vaccination. However, no correlation was seen between blood IgA ASC and duodenal IgA ASC after two doses of vaccine. Still, a correlation between numbers of CF-specific B cells in blood sampled from patients early during infection and numbers of duodenal B cells collected 1 week later was apparent (r = 0.70; n = 10; P = 0.03).  (+info)

Safety and immunogenicity of two different lots of the oral, killed enterotoxigenic escherichia coli-cholera toxin B subunit vaccine in Israeli young adults. (2/100)

Enterotoxigenic Escherichia coli (ETEC) is one of the leading causes of diarrhea among Israeli soldiers serving in field units. Two double-blind placebo-controlled, randomized trials were performed among 155 healthy volunteers to evaluate the safety and immunogenicity of different lots of the oral, killed ETEC vaccine consisting of two doses of whole cells plus recombinantly produced cholera toxin B subunit (rCTB). The two doses of vaccine lot E005 and the first dose of vaccine lot E003 were well tolerated by the volunteers. However, 5 (17%) vaccinees reported an episode of vomiting a few hours after the second dose of lot E003; none of the placebo recipients reported similar symptoms. Both lots of vaccine stimulated a rate of significant antibody-secreting cell (ASC) response to CTB and to colonization factor antigen I (CFA/I) after one or two doses, ranging from 85 to 100% and from 81 to 100%, respectively. The rate of ASC response to CS2, CS4, and CS5 was slightly lower than the rate of ASC response induced to CTB, CFA/I, and CS1. The second vaccine dose enhanced the response to CTB but did not increase the frequencies or magnitude of ASC responses to the other antigens. The two lots of the ETEC vaccine induced similar rates of serum antibody responses to CTB and CFA/I which were less frequent than the ASC responses to the same antigens. Based on these safety and immunogenicity data, an efficacy study of the ETEC vaccine is under way in the Israel Defense Force.  (+info)

Molecular variation among type IV pilin (bfpA) genes from diverse enteropathogenic Escherichia coli strains. (3/100)

Typical enteropathogenic Escherichia coli (EPEC) strains produce bundle-forming pili (BFP), type IVB fimbriae that have been implicated in EPEC virulence, antigenicity, autoaggregation, and localized adherence to epithelial cells (LA). BFP are polymers of bundlin, a pilin protein that is encoded by the bfpA gene found on a large EPEC plasmid. Striking sequence variation has previously been observed among type IV pilin genes of other gram-negative bacterial pathogens (e.g., Pseudomonas and Neisseria spp.). In contrast, the established sequences of bfpA genes from two distantly related prototype EPEC strains vary by only a single base pair. To determine whether bundlin sequences vary more extensively, we used PCR to amplify the bfpA genes from 19 EPEC strains chosen for their various serotypes and sites and years of isolation. Eight different bfpA alleles were identified by sequencing of the PCR products. These alleles can be classified into two major groups. The alpha group contains three alleles derived from strains carrying O55, O86, O111, O119, O127, or O128 somatic antigens. The beta group contains five alleles derived from strains carrying O55, O110, O128ab, O142, or nontypeable antigens. Sequence comparisons show that bundlin has highly conserved and variable regions, with most of the variation occurring in the C-terminal two-thirds of the protein. The results of multilocus enzyme electrophoresis support the hypothesis that bfpA sequences have spread horizontally across distantly related clonal lineages. Strains with divergent bundlin sequences express bundlin protein, produce BFP, and carry out autoaggregation and LA. However, four strains lack most or all of these phenotypes despite having an intact bfpA gene. These results have important implications for our understanding of bundlin structure, transmission of the bfp gene cluster among EPEC strains, and the role of bundlin variation in the evasion of host immune system responses.  (+info)

Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. (4/100)

The Shiga toxins Stx1 and Stx2 contribute to the development of enterohemorrhagic O157:H7 Escherichia coli-mediated colitis and hemolytic-uremic syndrome in humans. The Stx2 B subunit, which binds to globotriaosylceramide (GB3) receptors on target cells, was cloned. This involved replacing the Stx2 B subunit leader peptide nucleotide sequences with those from the Stx1 B subunit. The construct was expressed in the TOPP3 E. coli strain. The Stx2 B subunits from this strain assembled into a pentamer and bound to a GB3 receptor analogue. The cloned Stx2 B subunit was not cytotoxic to Vero cells or apoptogenic in Burkitt's lymphoma cells. Although their immune response to the Stx2 B subunit was variable, rabbits that developed Stx2 B subunit-specific antibodies, as determined by immunoblot and in vitro cytotoxicity neutralization assays, survived a challenge with Stx2 holotoxin. This is thought to be the first demonstration of the immunoprophylactic potential of the Stx2 B subunit.  (+info)

Oral administration of formaldehyde-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga-toxigenic Escherichia coli. (5/100)

Gastrointestinal disease caused by Shiga toxin-producing Escherichia coli (STEC) is frequently complicated by life-threatening toxin-induced systemic sequelae, including the hemolytic uremic syndrome. We previously constructed a recombinant bacterium displaying a Shiga toxin receptor mimic on its surface which neutralized Shiga toxins with very high efficiency. Moreover, oral administration of the live bacterium completely protected mice from challenge with virulent STEC. In this study, we investigated the protective capacity of formaldehyde-killed receptor mimic bacteria, as these are likely to be safer for administration to humans. The killed bacteria completely protected STEC-challenged mice when administered three times daily; incomplete protection was achieved using two doses per day. Commencement of therapy could be delayed for up to 48 h after challenge without diminishing protection, depending on the virulence of the challenge strain. Thus, administration of this agent early in the course of human STEC disease may prevent progression to life-threatening complications.  (+info)

Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. (6/100)

The passive infusion of antibodies elicited in rabbits with a detoxified J5 lipopolysaccharide (LPS)/group B meningococcal outer membrane protein complex vaccine protected neutropenic rats from heterologous lethal gram-negative bacterial infection. In this study, active immunization was studied in neutropenic rats infected with Pseudomonas aeruginosa, in the presence or absence of ceftazidime therapy, and with Klebsiella pneumoniae. This vaccine elicited a > 200-fold increase in anti-J5 LPS antibody, which remained elevated throughout the duration of cyclophosphamide-induced neutropenia and for < or = 3 months. There was improved survival among immunized versus control animals: 48% (13/28) versus 7% (2/29) in Pseudomonas-challenged rats; 61% (11/18) versus 0% (0/10) in Pseudomonas- and ceftazidime-treated rats; and 64% (9/14) versus 13% (2/15) in Klebsiella-challenged rats (P < 0.01 for each comparison). Immunized animals had lower levels of bacteria in organs and lower levels of circulating endotoxin at the onset of fever. In conclusion, active immunization with an anti-endotoxin vaccine improved survival after infection with > or = 2 heterologous, clinically relevant bacterial species in immunocompromised animals. Active immunization with this vaccine merits further investigation.  (+info)

Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine. (7/100)

The immunogenicity of different preparations of an oral inactivated enterotoxigenic Escherichia coli (ETEC) vaccine was evaluated in Swedish volunteers previously unexposed to ETEC infection. The vaccine preparations consisted of recombinant cholera toxin B subunit (CTB) and various amounts of formalin-killed whole bacteria expressing the most prevalent colonization factor antigens (CFAs). Significant immunoglobulin A (IgA) antibody-secreting cell (ASC) responses against CTB and the various CFA components were seen in a majority of volunteers after two doses of ETEC vaccine independent of the vaccine lot given. The IgA ASC responses against CTB were significantly higher after the second than after the first immunization, whereas the CFA-specific IgA ASC responses were almost comparable after the first and second doses of ETEC vaccine. Two immunizations with one-third of a full dose of CFA-ETEC bacteria induced lower frequencies of IgA ASC responses against all the different CFAs than two full vaccine doses, i.e., 63 versus 80% for CFA/I, 56 versus 70% for CS1, 31 versus 65% for CS2, and 56 versus 75% for CS4. The proportion of vaccinees responding with rises in the titer of serum IgA antibody against the various CFA antigens was also lower after immunization with the reduced dose of CFA-ETEC bacteria. These findings suggest that measurements of circulating IgA ASCs can be used not only for qualitative but also for quantitative assessments of the immunogenicity of individual fimbrial antigens in various preparations of ETEC vaccine.  (+info)

Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans. (8/100)

Enterotoxigenic Escherichia coli (ETEC) is a leading cause of diarrhea in travelers to countries where the disease is endemic and causes a major disease burden in the indigenous population, particularly children. We describe here the generation and preclinical characterization of candidate strains of ETEC which are intended to provide the basis of a live attenuated oral vaccine to prevent this disease. It has been shown previously that a spontaneously arising toxin-negative variant ETEC strain, E1392/75-2A, could confer 75% protection against challenge when administered to volunteers. Unfortunately this strain induced mild diarrhea in 15% of recipients. To eliminate the unacceptable reactogenicity of strain E1392/75-2A, it was further attenuated by introducing three different combinations of defined deletion mutations into the chromosome. A mouse intranasal model of immunization was developed and used to show that all of the strains were immunogenic. Immune responses against colonization factor antigens (CFAs) were particularly strong when the bacterial inocula were grown on "CFA agar," which induces strong expression of these antigens. Two of the strains were selected for a phase I dose escalation safety study with healthy adult volunteers. Freshly grown organisms were harvested from CFA agar plates and administered to volunteers as a suspension containing from 5 x 10(7) to 5 x 10(9) CFU. The vaccine was well tolerated at all doses and induced significant immune responses in all recipients at the highest dose of either strain. The results provide the basis for further clinical evaluation of these vaccine candidates.  (+info)

Escherichia coli (E. coli) vaccines are designed to protect against infections caused by various strains of the E. coli bacterium. These vaccines typically contain inactivated or attenuated (weakened) forms of the bacteria, which stimulate an immune response when introduced into the body. The immune system learns to recognize and fight off the specific strain of E. coli used in the vaccine, providing protection against future infections with that strain.

There are several types of E. coli vaccines available or in development, including:

1. Shiga toxin-producing E. coli (STEC) vaccines: These vaccines protect against STEC strains, such as O157:H7 and non-O157 STECs, which can cause severe illness, including hemorrhagic colitis and hemolytic uremic syndrome (HUS).
2. Enterotoxigenic E. coli (ETEC) vaccines: These vaccines target ETEC strains that are a common cause of traveler's diarrhea in people visiting areas with poor sanitation.
3. Enteropathogenic E. coli (EPEC) vaccines: EPEC strains can cause persistent diarrhea, especially in young children in developing countries. Vaccines against these strains are still in the research and development stage.
4. Extraintestinal pathogenic E. coli (ExPEC) vaccines: These vaccines aim to protect against ExPEC strains that can cause urinary tract infections, sepsis, and meningitis.

It is important to note that different E. coli vaccines are designed for specific purposes and may not provide cross-protection against other strains or types of E. coli infections.

Escherichia coli (E. coli) infections refer to illnesses caused by the bacterium E. coli, which can cause a range of symptoms depending on the specific strain and site of infection. The majority of E. coli strains are harmless and live in the intestines of healthy humans and animals. However, some strains, particularly those that produce Shiga toxins, can cause severe illness.

E. coli infections can occur through various routes, including contaminated food or water, person-to-person contact, or direct contact with animals or their environments. Common symptoms of E. coli infections include diarrhea (often bloody), abdominal cramps, nausea, and vomiting. In severe cases, complications such as hemolytic uremic syndrome (HUS) can occur, which may lead to kidney failure and other long-term health problems.

Preventing E. coli infections involves practicing good hygiene, cooking meats thoroughly, avoiding cross-contamination of food during preparation, washing fruits and vegetables before eating, and avoiding unpasteurized dairy products and juices. Prompt medical attention is necessary if symptoms of an E. coli infection are suspected to prevent potential complications.

Bacterial vaccines are types of vaccines that are created using bacteria or parts of bacteria as the immunogen, which is the substance that triggers an immune response in the body. The purpose of a bacterial vaccine is to stimulate the immune system to develop protection against specific bacterial infections.

There are several types of bacterial vaccines, including:

1. Inactivated or killed whole-cell vaccines: These vaccines contain entire bacteria that have been killed or inactivated through various methods, such as heat or chemicals. The bacteria can no longer cause disease, but they still retain the ability to stimulate an immune response.
2. Subunit, protein, or polysaccharide vaccines: These vaccines use specific components of the bacterium, such as proteins or polysaccharides, that are known to trigger an immune response. By using only these components, the vaccine can avoid using the entire bacterium, which may reduce the risk of adverse reactions.
3. Live attenuated vaccines: These vaccines contain live bacteria that have been weakened or attenuated so that they cannot cause disease but still retain the ability to stimulate an immune response. This type of vaccine can provide long-lasting immunity, but it may not be suitable for people with weakened immune systems.

Bacterial vaccines are essential tools in preventing and controlling bacterial infections, reducing the burden of diseases such as tuberculosis, pneumococcal disease, meningococcal disease, and Haemophilus influenzae type b (Hib) disease. They work by exposing the immune system to a harmless form of the bacteria or its components, which triggers the production of antibodies and memory cells that can recognize and fight off future infections with that same bacterium.

It's important to note that while vaccines are generally safe and effective, they may cause mild side effects such as pain, redness, or swelling at the injection site, fever, or fatigue. Serious side effects are rare but can occur, so it's essential to consult with a healthcare provider before receiving any vaccine.

'Escherichia coli (E. coli) proteins' refer to the various types of proteins that are produced and expressed by the bacterium Escherichia coli. These proteins play a critical role in the growth, development, and survival of the organism. They are involved in various cellular processes such as metabolism, DNA replication, transcription, translation, repair, and regulation.

E. coli is a gram-negative, facultative anaerobe that is commonly found in the intestines of warm-blooded organisms. It is widely used as a model organism in scientific research due to its well-studied genetics, rapid growth, and ability to be easily manipulated in the laboratory. As a result, many E. coli proteins have been identified, characterized, and studied in great detail.

Some examples of E. coli proteins include enzymes involved in carbohydrate metabolism such as lactase, sucrase, and maltose; proteins involved in DNA replication such as the polymerases, single-stranded binding proteins, and helicases; proteins involved in transcription such as RNA polymerase and sigma factors; proteins involved in translation such as ribosomal proteins, tRNAs, and aminoacyl-tRNA synthetases; and regulatory proteins such as global regulators, two-component systems, and transcription factors.

Understanding the structure, function, and regulation of E. coli proteins is essential for understanding the basic biology of this important organism, as well as for developing new strategies for combating bacterial infections and improving industrial processes involving bacteria.

'Escherichia coli' (E. coli) is a type of gram-negative, facultatively anaerobic, rod-shaped bacterium that commonly inhabits the intestinal tract of humans and warm-blooded animals. It is a member of the family Enterobacteriaceae and one of the most well-studied prokaryotic model organisms in molecular biology.

While most E. coli strains are harmless and even beneficial to their hosts, some serotypes can cause various forms of gastrointestinal and extraintestinal illnesses in humans and animals. These pathogenic strains possess virulence factors that enable them to colonize and damage host tissues, leading to diseases such as diarrhea, urinary tract infections, pneumonia, and sepsis.

E. coli is a versatile organism with remarkable genetic diversity, which allows it to adapt to various environmental niches. It can be found in water, soil, food, and various man-made environments, making it an essential indicator of fecal contamination and a common cause of foodborne illnesses. The study of E. coli has contributed significantly to our understanding of fundamental biological processes, including DNA replication, gene regulation, and protein synthesis.

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. It typically contains an agent that resembles the disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it encounters in the future.

Vaccines can be prophylactic (to prevent or ameliorate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (to fight disease that is already present). The administration of vaccines is called vaccination. Vaccinations are generally administered through needle injections, but can also be administered by mouth or sprayed into the nose.

The term "vaccine" comes from Edward Jenner's 1796 use of cowpox to create immunity to smallpox. The first successful vaccine was developed in 1796 by Edward Jenner, who showed that milkmaids who had contracted cowpox did not get smallpox. He reasoned that exposure to cowpox protected against smallpox and tested his theory by injecting a boy with pus from a cowpox sore and then exposing him to smallpox, which the boy did not contract. The word "vaccine" is derived from Variolae vaccinae (smallpox of the cow), the term devised by Jenner to denote cowpox. He used it in 1798 during a conversation with a fellow physician and later in the title of his 1801 Inquiry.

Escherichia coli (E. coli) O157 is a serotype of the bacterium E. coli that is associated with foodborne illness. This strain is pathogenic and produces Shiga toxins, which can cause severe damage to the lining of the small intestine and potentially lead to hemorrhagic diarrhea and kidney failure. E. coli O157 is often transmitted through contaminated food, particularly undercooked ground beef, as well as raw or unpasteurized dairy products, fruits, and vegetables. It can also be spread through contact with infected individuals or animals, especially in settings like farms, petting zoos, and swimming pools. Proper food handling, cooking, and hygiene practices are crucial to preventing E. coli O157 infections.

Bacterial proteins are a type of protein that are produced by bacteria as part of their structural or functional components. These proteins can be involved in various cellular processes, such as metabolism, DNA replication, transcription, and translation. They can also play a role in bacterial pathogenesis, helping the bacteria to evade the host's immune system, acquire nutrients, and multiply within the host.

Bacterial proteins can be classified into different categories based on their function, such as:

1. Enzymes: Proteins that catalyze chemical reactions in the bacterial cell.
2. Structural proteins: Proteins that provide structural support and maintain the shape of the bacterial cell.
3. Signaling proteins: Proteins that help bacteria to communicate with each other and coordinate their behavior.
4. Transport proteins: Proteins that facilitate the movement of molecules across the bacterial cell membrane.
5. Toxins: Proteins that are produced by pathogenic bacteria to damage host cells and promote infection.
6. Surface proteins: Proteins that are located on the surface of the bacterial cell and interact with the environment or host cells.

Understanding the structure and function of bacterial proteins is important for developing new antibiotics, vaccines, and other therapeutic strategies to combat bacterial infections.

A bacterial gene is a segment of DNA (or RNA in some viruses) that contains the genetic information necessary for the synthesis of a functional bacterial protein or RNA molecule. These genes are responsible for encoding various characteristics and functions of bacteria such as metabolism, reproduction, and resistance to antibiotics. They can be transmitted between bacteria through horizontal gene transfer mechanisms like conjugation, transformation, and transduction. Bacterial genes are often organized into operons, which are clusters of genes that are transcribed together as a single mRNA molecule.

It's important to note that the term "bacterial gene" is used to describe genetic elements found in bacteria, but not all genetic elements in bacteria are considered genes. For example, some DNA sequences may not encode functional products and are therefore not considered genes. Additionally, some bacterial genes may be plasmid-borne or phage-borne, rather than being located on the bacterial chromosome.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

Inactivated vaccines, also known as killed or non-live vaccines, are created by using a version of the virus or bacteria that has been grown in a laboratory and then killed or inactivated with chemicals, heat, or radiation. This process renders the organism unable to cause disease, but still capable of stimulating an immune response when introduced into the body.

Inactivated vaccines are generally considered safer than live attenuated vaccines since they cannot revert back to a virulent form and cause illness. However, they may require multiple doses or booster shots to maintain immunity because the immune response generated by inactivated vaccines is not as robust as that produced by live vaccines. Examples of inactivated vaccines include those for hepatitis A, rabies, and influenza (inactivated flu vaccine).

A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.

A plasmid is a small, circular, double-stranded DNA molecule that is separate from the chromosomal DNA of a bacterium or other organism. Plasmids are typically not essential for the survival of the organism, but they can confer beneficial traits such as antibiotic resistance or the ability to degrade certain types of pollutants.

Plasmids are capable of replicating independently of the chromosomal DNA and can be transferred between bacteria through a process called conjugation. They often contain genes that provide resistance to antibiotics, heavy metals, and other environmental stressors. Plasmids have also been engineered for use in molecular biology as cloning vectors, allowing scientists to replicate and manipulate specific DNA sequences.

Plasmids are important tools in genetic engineering and biotechnology because they can be easily manipulated and transferred between organisms. They have been used to produce vaccines, diagnostic tests, and genetically modified organisms (GMOs) for various applications, including agriculture, medicine, and industry.

Bacterial DNA refers to the genetic material found in bacteria. It is composed of a double-stranded helix containing four nucleotide bases - adenine (A), thymine (T), guanine (G), and cytosine (C) - that are linked together by phosphodiester bonds. The sequence of these bases in the DNA molecule carries the genetic information necessary for the growth, development, and reproduction of bacteria.

Bacterial DNA is circular in most bacterial species, although some have linear chromosomes. In addition to the main chromosome, many bacteria also contain small circular pieces of DNA called plasmids that can carry additional genes and provide resistance to antibiotics or other environmental stressors.

Unlike eukaryotic cells, which have their DNA enclosed within a nucleus, bacterial DNA is present in the cytoplasm of the cell, where it is in direct contact with the cell's metabolic machinery. This allows for rapid gene expression and regulation in response to changing environmental conditions.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

Escherichia coli (E. coli) K12 is a strain of the bacterium E. coli that is commonly used in scientific research. It was originally isolated from the human intestine and has been well-studied due to its relatively harmless nature compared to other strains of E. coli that can cause serious illness.

The "K12" designation refers to a specific set of genetic characteristics that distinguish this strain from others. It is a non-pathogenic, or non-harmful, strain that is often used as a model organism in molecular biology and genetics research. Researchers have developed many tools and resources for studying E. coli K12, including a complete genome sequence and extensive collections of mutant strains.

E. coli K12 is not typically found in the environment and is not associated with disease in healthy individuals. However, it can be used as an indicator organism to detect fecal contamination in water supplies, since it is commonly present in the intestines of warm-blooded animals.

Molecular cloning is a laboratory technique used to create multiple copies of a specific DNA sequence. This process involves several steps:

1. Isolation: The first step in molecular cloning is to isolate the DNA sequence of interest from the rest of the genomic DNA. This can be done using various methods such as PCR (polymerase chain reaction), restriction enzymes, or hybridization.
2. Vector construction: Once the DNA sequence of interest has been isolated, it must be inserted into a vector, which is a small circular DNA molecule that can replicate independently in a host cell. Common vectors used in molecular cloning include plasmids and phages.
3. Transformation: The constructed vector is then introduced into a host cell, usually a bacterial or yeast cell, through a process called transformation. This can be done using various methods such as electroporation or chemical transformation.
4. Selection: After transformation, the host cells are grown in selective media that allow only those cells containing the vector to grow. This ensures that the DNA sequence of interest has been successfully cloned into the vector.
5. Amplification: Once the host cells have been selected, they can be grown in large quantities to amplify the number of copies of the cloned DNA sequence.

Molecular cloning is a powerful tool in molecular biology and has numerous applications, including the production of recombinant proteins, gene therapy, functional analysis of genes, and genetic engineering.

A viral vaccine is a biological preparation that introduces your body to a specific virus in a way that helps your immune system build up protection against the virus without causing the illness. Viral vaccines can be made from weakened or inactivated forms of the virus, or parts of the virus such as proteins or sugars. Once introduced to the body, the immune system recognizes the virus as foreign and produces an immune response, including the production of antibodies. These antibodies remain in the body and provide immunity against future infection with that specific virus.

Viral vaccines are important tools for preventing infectious diseases caused by viruses, such as influenza, measles, mumps, rubella, polio, hepatitis A and B, rabies, rotavirus, chickenpox, shingles, and some types of cancer. Vaccination programs have led to the control or elimination of many infectious diseases that were once common.

It's important to note that viral vaccines are not effective against bacterial infections, and separate vaccines must be developed for each type of virus. Additionally, because viruses can mutate over time, it is necessary to update some viral vaccines periodically to ensure continued protection.

A bioreactor is a device or system that supports and controls the conditions necessary for biological organisms, cells, or tissues to grow and perform their specific functions. It provides a controlled environment with appropriate temperature, pH, nutrients, and other factors required for the desired biological process to occur. Bioreactors are widely used in various fields such as biotechnology, pharmaceuticals, agriculture, and environmental science for applications like production of therapeutic proteins, vaccines, biofuels, enzymes, and wastewater treatment.

Antifoaming agents are substances that prevent or reduce the formation of foam in liquids. They are often used in industrial processes, such as manufacturing and food production, to minimize the negative effects of foam on equipment performance, product quality, and safety. In a medical context, antifoaming agents may be used in certain medications, intravenous (IV) fluids, or enteral feedings to prevent or treat foaming that can interfere with proper administration or absorption of the treatment.

These agents work by reducing surface tension, promoting bubble rupture, or absorbing excess gases. Common antifoaming agents include silicone-based compounds, such as dimethicone and simethicone, as well as other substances like polyoxyethylene sorbitan monostearate (Tween) and alcohols.

In some cases, antifoaming agents may be used during medical procedures to prevent or treat the accumulation of foam in body cavities, such as the stomach or lungs. For instance, simethicone is sometimes administered to newborns with meconium ileus (a bowel obstruction caused by thickened meconium) to help reduce the formation of gas and facilitate the passage of meconium. Similarly, antifoaming agents may be used in mechanical ventilation to prevent or treat pulmonary air leaks and improve oxygenation.

While antifoaming agents are generally considered safe when used as directed, they can have side effects, particularly if overused or misused. Potential adverse reactions include gastrointestinal symptoms like diarrhea, nausea, or bloating, as well as allergic reactions in sensitive individuals. It is essential to follow the recommended dosage and administration guidelines provided by a healthcare professional when using antifoaming agents for medical purposes.

Bioengineering, also known as biological engineering, is defined as the application of principles and methods from engineering to study, modify, and control biological systems, often with the goal of creating new technologies or improving existing ones. This field combines knowledge and expertise from various disciplines, including biology, chemistry, physics, mathematics, and computer science, to solve complex problems related to health, medicine, agriculture, and the environment.

Bioengineers may work on a wide range of projects, such as developing new medical devices or therapies, designing synthetic biological systems for industrial applications, creating biosensors for environmental monitoring, or engineering tissues and organs for transplantation. They use a variety of tools and techniques, including genetic engineering, biomaterials, computational modeling, and nanotechnology, to design and build novel biological systems that can perform specific functions or solve practical problems.

Bioengineering has the potential to transform many areas of science and technology, with significant implications for human health, sustainability, and innovation. As such, it is an exciting and rapidly growing field that offers many opportunities for interdisciplinary collaboration and discovery.

I'm sorry for any confusion, but "Polypropylenes" does not have a medical definition as it is not a medical term. Polypropylene is a type of plastic that is used in various medical and non-medical applications. It is a thermoplastic polymer resin that is produced by the polymerization of propylene.

In the medical field, polypropylene is sometimes used to make single-use surgical instruments, sutures, and medical devices due to its resistance to heat, chemicals, and electricity. It is also biocompatible, meaning it can be safely used in the body without causing adverse reactions. However, "Polypropylenes" as a medical term is not recognized or used in the medical community.

Spectinomycin is an antibiotic that belongs to the aminoglycoside family. It works by binding to the 30S subunit of the bacterial ribosome, thereby inhibiting protein synthesis and leading to bacterial cell death. Spectinomycin is primarily used to treat infections caused by susceptible strains of Gram-negative and Gram-positive bacteria, including gonorrhea, penicillin-resistant streptococci, and some anaerobes. It is administered parenterally (usually intramuscularly) and has a relatively narrow spectrum of activity compared to other aminoglycosides. Spectinomycin is not commonly used in many countries due to the availability of alternative antibiotics with broader spectra and fewer side effects.

I'm sorry for any confusion, but "Switzerland" is not a medical term or concept. Switzerland is a country in Europe, known officially as the Swiss Confederation. If you have any questions about medical terminology or concepts, I'd be happy to try and help answer those for you!

Fermentation is a metabolic process in which an organism converts carbohydrates into alcohol or organic acids using enzymes. In the absence of oxygen, certain bacteria, yeasts, and fungi convert sugars into carbon dioxide, hydrogen, and various end products, such as alcohol, lactic acid, or acetic acid. This process is commonly used in food production, such as in making bread, wine, and beer, as well as in industrial applications for the production of biofuels and chemicals.

Cholera is an infectious disease caused by the bacterium Vibrio cholerae, which is usually transmitted through contaminated food or water. The main symptoms of cholera are profuse watery diarrhea, vomiting, and dehydration, which can lead to electrolyte imbalances, shock, and even death if left untreated. Cholera remains a significant public health concern in many parts of the world, particularly in areas with poor sanitation and hygiene. The disease is preventable through proper food handling, safe water supplies, and improved sanitation, as well as vaccination for those at high risk.

Rotavirus is a genus of double-stranded RNA virus in the Reoviridae family, which is a leading cause of severe diarrhea and gastroenteritis in young children and infants worldwide. The virus infects and damages the cells lining the small intestine, resulting in symptoms such as vomiting, watery diarrhea, abdominal cramps, and fever.

Rotavirus is highly contagious and can be spread through contact with infected individuals or contaminated surfaces, food, or water. The virus is typically transmitted via the fecal-oral route, meaning that it enters the body through the mouth after coming into contact with contaminated hands, objects, or food.

Rotavirus infections are often self-limiting and resolve within a few days to a week, but severe cases can lead to dehydration, hospitalization, and even death, particularly in developing countries where access to medical care and rehydration therapy may be limited. Fortunately, there are effective vaccines available that can prevent rotavirus infection and reduce the severity of symptoms in those who do become infected.

Diarrhea is a condition in which an individual experiences loose, watery stools frequently, often exceeding three times a day. It can be acute, lasting for several days, or chronic, persisting for weeks or even months. Diarrhea can result from various factors, including viral, bacterial, or parasitic infections, food intolerances, medications, and underlying medical conditions such as inflammatory bowel disease or irritable bowel syndrome. Dehydration is a potential complication of diarrhea, particularly in severe cases or in vulnerable populations like young children and the elderly.

According to the World Health Organization (WHO), Rotavirus is the most common cause of severe diarrhea among children under 5 years of age. It is responsible for around 215,000 deaths among children in this age group each year.

Rotavirus infection causes inflammation of the stomach and intestines, resulting in symptoms such as vomiting, watery diarrhea, and fever. The virus is transmitted through the fecal-oral route, often through contaminated hands, food, or water. It can also be spread through respiratory droplets when an infected person coughs or sneezes.

Rotavirus infections are highly contagious and can spread rapidly in communities, particularly in settings where children are in close contact with each other, such as child care centers and schools. The infection is usually self-limiting and resolves within a few days, but severe cases can lead to dehydration and require hospitalization.

Prevention measures include good hygiene practices, such as handwashing with soap and water, safe disposal of feces, and rotavirus vaccination. The WHO recommends the inclusion of rotavirus vaccines in national immunization programs to reduce the burden of severe diarrhea caused by rotavirus infection.

Rotavirus vaccines are preventive measures used to protect against rotavirus infections, which are the leading cause of severe diarrhea and dehydration among infants and young children worldwide. These vaccines contain weakened or inactivated forms of the rotavirus, a pathogen that infects and causes symptoms by multiplying inside cells lining the small intestine.

The weakened or inactivated virus in the vaccine stimulates an immune response in the body, enabling it to recognize and fight off future rotavirus infections more effectively. The vaccines are usually administered orally, as a liquid droplet or on a sugar cube, to mimic natural infection through the gastrointestinal tract.

There are currently two licensed rotavirus vaccines available globally:

1. Rotarix (GlaxoSmithKline): This vaccine contains an attenuated (weakened) strain of human rotavirus and is given in a two-dose series, typically at 2 and 4 months of age.
2. RotaTeq (Merck): This vaccine contains five reassortant viruses, combining human and animal strains to provide broader protection. It is administered in a three-dose series, usually at 2, 4, and 6 months of age.

Rotavirus vaccines have been shown to significantly reduce the incidence of severe rotavirus gastroenteritis and related hospitalizations among infants and young children. The World Health Organization (WHO) recommends the inclusion of rotavirus vaccination in national immunization programs, particularly in countries with high child mortality rates due to diarrheal diseases.

Enterotoxigenic Escherichia coli (ETEC) is a type of diarrheagenic E. coli that causes traveler's diarrhea and diarrheal diseases in infants in developing countries. It produces one or two enterotoxins, known as heat-labile toxin (LT) and heat-stable toxin (ST), which cause the intestinal lining to secrete large amounts of water and electrolytes, resulting in watery diarrhea. ETEC is often transmitted through contaminated food or water and is a common cause of traveler's diarrhea in people traveling to areas with poor sanitation. It can also cause outbreaks in refugee camps, nursing homes, and other institutional settings. Prevention measures include avoiding consumption of untreated water and raw or undercooked foods, as well as practicing good personal hygiene.

Cholera toxin is a protein toxin produced by the bacterium Vibrio cholerae, which causes the infectious disease cholera. The toxin is composed of two subunits, A and B, and its primary mechanism of action is to alter the normal function of cells in the small intestine.

The B subunit of the toxin binds to ganglioside receptors on the surface of intestinal epithelial cells, allowing the A subunit to enter the cell. Once inside, the A subunit activates a signaling pathway that results in the excessive secretion of chloride ions and water into the intestinal lumen, leading to profuse, watery diarrhea, dehydration, and other symptoms associated with cholera.

Cholera toxin is also used as a research tool in molecular biology and immunology due to its ability to modulate cell signaling pathways. It has been used to study the mechanisms of signal transduction, protein trafficking, and immune responses.

"Status of vaccine research and development for enterotoxigenic Escherichia coli". Vaccine. 34 (26): 2880-86. doi:10.1016/j. ... Wikispecies has information related to Escherichia coli. Wikimedia Commons has media related to Escherichia coli. EcoCyc - ... coli K-12. Uropathogenic Escherichia coli (UPEC) AlignACE Matrices that search for additional binding sites in the E. coli ... coli helped produce E. coli O157:H7, the Shiga toxin-producing strain of E. coli. E. coli encompasses an enormous population of ...
Modified E. coli have been used in vaccine development, bioremediation, and production of immobilised enzymes. E. coli have ... Escherichia coli (/ˌɛʃɪˈrɪkiə ˈkoʊlaɪ/; commonly abbreviated E. coli) is a Gram-negative gammaproteobacterium commonly found in ... following which Escherichia coli was used for linkage mapping studies. Four of the many E. coli strains (K-12, B, C, and W) are ... "Production of glycoprotein vaccines in Escherichia coli". Microbial Cell Factories. 9 (61): 494-7. doi:10.1186/1475-2859-9-61. ...
Ahmed, T; Bhuiyan, TR; Zaman, K; Sinclair, D; Qadri, F (5 July 2013). "Vaccines for preventing enterotoxigenic Escherichia coli ... The bacteria enterotoxigenic Escherichia coli (ETEC) are typically the most common except in Southeast Asia, where ... Enterotoxigenic Escherichia coli (ETEC). Archived 2012-05-15 at the Wayback Machine "World Health Organization. Shigellosis". ... The most common causative agent isolated in countries surveyed has been enterotoxigenic Escherichia coli (ETEC). ...
... Vaccine Resource Library: Shigellosis and enterotoxigenic Escherichia coli (ETEC) (CS1 errors ... Enterotoxigenic Escherichia coli (ETEC) is a type of Escherichia coli and one of the leading bacterial causes of diarrhea in ... "Status of vaccine research and development for enterotoxigenic Escherichia coli". Vaccine. 34 (26): 2880-2886. doi:10.1016/j. ... PATH, bvgh (March 2011). "The Case for Investment in Enterotoxigenic Escherichia coli Vaccines" (PDF). Retrieved 2 May 2012. {{ ...
"ESCHERICHIA COLI". Public Health Agency of Canada. 2012-04-30. Retrieved 2015-06-02. "Signs & Symptoms". Centers for Disease ... Bubeck SS, Dube PH (September 2007). "Yersinia pestis CO92ΔyopH Is a Potent Live, Attenuated Plague Vaccine". Clin. Vaccine ... The most frequent cause is Escherichia coli. Urine is typically sterile but contains a variety of salts, and waste products ... "Diphtheria vaccine" (PDF). Wkly Epidemiol Rec. 81 (3): 24-32. 20 January 2006. PMID 16671240. Archived (PDF) from the original ...
"Escherichia coli-derived virus-like particles in vaccine development". npj Vaccines. 2 (1): 3. doi:10.1038/s41541-017-0006-8. ... have run clinical trials of their VLP flu vaccines. Several VLP vaccines for COVID-19, including Novavax, are under development ... compared to 9 months for traditional vaccines. In early clinical trials, VLP vaccines for influenza appeared to provide ... The first VLP vaccine that addresses malaria, Mosquirix, (RTS,S) has been approved by EU regulators. It was expressed in yeast ...
Smallpox vaccine Varicella vaccine Yellow fever vaccine Zoster/shingles vaccine Enterotoxigenic Escherichia coli vaccine Tick- ... Anthrax vaccine Cholera vaccine Plague vaccine Salmonella vaccine Tuberculosis vaccine Typhoid vaccine Live attenuated ... oral polio vaccine, recombinant live attenuated cholera vaccine, oral typhoid vaccine, oral rotavirus vaccine) Oral vaccines or ... mumps and rubella vaccine, varicella vaccine, yellow fever vaccine) Intradermal (e.g. tuberculosis vaccine, smallpox vaccine) ...
Cholera and enterotoxigenic escherichia coli (ETEC) travellers' diarrhea vaccine: Canadian Immunization Guide. Health Canada ( ... Inactivated vaccines, Vaccines, World Health Organization essential medicines (vaccines), Wikipedia medicine articles ready to ... The first cholera vaccines were developed in the late 1900s. They were the first widely used vaccine that was made in a ... A cholera vaccine is a vaccine that is effective at preventing cholera. For the first six months after vaccination it provides ...
They found over 600 possible antigens, which were tested by expression in Escherichia coli. The most universally applicable ... Later, the vaccine was proven to be safe and effective in adult humans. During the development of the MenB vaccine, scientists ... A Streptococcus and B Streptococcus vaccines were two of the first Reverse Vaccines created. Because those bacterial strains ... Vaccine Design: Methods and Protocols: Volume 1: Vaccines for Human Diseases, New York, NY: Springer Publishing; Humana Press, ...
For example, vaccines against Shigella and enterotoxigenic Escherichia coli (ETEC), which are two of the leading bacterial ... "Enterotoxigenic Escherichia coli (ETEC)". Diarrhoeal Diseases. Archived from the original on 15 May 2012. Retrieved 3 May 2012 ... In children, bacteria are the cause in about 15% of cases, with the most common types being Escherichia coli, Salmonella, ... The oral cholera vaccine has been found to be 50-60% effective over two years. There are a number of vaccines against ...
MBP is encoded by the malE gene of Escherichia coli. The malE gene codes for a precursor polypeptide (396 amino acid residues) ... Vaccine. 19 (7-8): 684-93. doi:10.1016/s0264-410x(00)00267-x. PMID 11115689. Bedouelle H, Duplay P (February 1988). "Production ... Maltose-binding protein (MBP) is a part of the maltose/maltodextrin system of Escherichia coli, which is responsible for the ... Bedouelle H (November 1983). "Mutations in the promoter regions of the malEFG and malK-lamB operons of Escherichia coli K12". ...
"The development and early clinical testing of the ExPEC4V conjugate vaccine against uropathogenic Escherichia coli". Clinical ... Escherichia coli is the single most common microorganism, followed by Klebsiella and Proteus spp., to cause urinary tract ... The most common cause of infection is Escherichia coli, though other bacteria or fungi may sometimes be the cause. Risk factors ... Uropathogenic E. coli from the gut is the cause of 80-85% of community-acquired urinary tract infections, with Staphylococcus ...
Karkut observed a significant reduction in the incidence of Escherichia coli (55% to 23%), Group B Streptococci (37% to 10%), ... Siegrist C (2017). "Vaccine immunology". In Plotkin S, Orenstein W, Offit P, Edwards KM (eds.). Plotkin's Vaccines (7th ed.). ... the mucosal surfaces of the vaginal introitus are colonized by Escherichia coli and Enterococci, rather than Lactobacilli. Reid ... "Secretory IgA and mucin-mediated biofilm formation by environmental strains of Escherichia coli: role of type 1 pili". ...
... scientific achievements lie in enteric infections and vaccines including Vibrio cholerae and enterotoxigenic Escherichia coli- ... and vaccine development. She endeavored to introduce a new cheap oral cholera vaccine in Bangladesh in replacement of Dukoral, ... She demonstrated the efficacy of Shanchol vaccine in mass population in slam areas in Dhaka, then worked to have it adopted as ... Currently, she is the senior scientist and director of Centre for Vaccine Science at ICDDR,B. Qadri has focused her research on ...
She researched the genetic mechanism and control of host attachment by uropathogenic Escherichia coli as part of the Normark ... She became the program manager of the Vaccines and Immunology Group in 1997. Tennent has researched and given keynote ... Tennent, J. M.; Lindberg, F.; Normark, S. (May 1990). "Integrity of Escherichia coli P pili during biogenesis: properties and ... "Horizontal gene transfer of the Escherichia coli pap and prs pili operons as a mechanism for the development of tissue-specific ...
Maize as production and delivery vehicle of edible vaccines against the enterotoxigenic Escherichia coli and the swine ...
... contributed to the development of a vaccine together with Ann-Mari Svennerholm against Enterotoxigenic Escherichia coli (ETEC ... Unlike previous injected cholera vaccines, which conferred weak protection for only a few months, Dukoralâ„¢ oral cholera vaccine ... prequalified oral cholera vaccine. The vaccine, which was tested in large field trials in Bangladesh, Peru, Mozambique and ... the other organizations include the Global Alliance for Vaccines and Immunization (GAVI) and the International Vaccine ...
... the adhesin of uropathogenic Escherichia coli (UPEC). Work with E. coli stems from observations of human acquired immunity. ... The study of adhesins as a point of exploitation for vaccines comes from early studies which indicated that an important ... Escherichia coli strains most known for causing diarrhea can be found in the intestinal tissue of pigs and humans where they ... Escherichia coli FimH provides an example of conformation specific immune response which enhances impact on the protein. By ...
New vaccines against rotavirus, Shigella, Enterotoxigenic Escherichia coli (ETEC), and cholera are under development, as well ... Shiga-toxin producing Escherichia coli, such as E coli o157:h7, are the most common cause of infectious bloody diarrhea in the ... and some strains of Escherichia coli are also a frequent cause. In the elderly, particularly those who have been treated with ... There are concerns that antibiotics may increase the risk of hemolytic uremic syndrome in people infected with Escherichia coli ...
bacteria like Escherichia coli, Proteus mirabilis, Enterococcus faecium, Staphylococcus cohnii, Clostridium perfringens, ... Reovirus vaccines are advocated (in dams or in broilers) but do not entirely solve the problem. General hygiene and correct ...
... of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study". Vaccine ... "Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin ... "Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double ... Vaccine. 27 (Suppl 6): G60-6. doi:10.1016/j.vaccine.2009.10.031. PMID 20006142. Kenney, RT; Frech, SA; Muenz, LR; Villar, CP; ...
... stage involves the molecular cloning of DNA plasmids that code for the spike protein by infusing them into Escherichia coli ... American COVID-19 vaccines, German COVID-19 vaccines, Pfizer, Products introduced in 2020, RNA vaccines, COVID-19 vaccination ... far above the requirements of the vaccine. Before COVID‑19 vaccines, a vaccine for an infectious disease had never before been ... The vaccine is used to reduce morbidity and mortality from COVID-19. The vaccine is supplied in a multidose vial as "a white to ...
... with the thesis entitled The regulation of alkaline phosphatase by the sigma factor S of RNA polymerase from Escherichia coli. ... Vaccine hesitancy: old story, same mistakes. JOURNAL HEALTH NPEPS, v. 6, p. e5876, 2021 Taschner, Natalia; Yagil, Ezra; Spira, ... Beny (February 25, 2013). "The effect of IHF on sigmaS selectivity of the phoA and pst promoters of Escherichia coli". Archives ... "The effect of the rpoSam allele on gene expression and stress resistance in Escherichia coli". Archives of Microbiology. ...
The fusion chimeric gene expressed in Escherichia coli. The sequence of the chimeric protein is available from the patent.[2] ... "COVID-19 vaccine: WHO in talks with Russia on its second vaccine EpiVacCorona". mint. 16 October 2020. Retrieved 9 June 2021. " ... 2743593). The patented vaccine composition contains 2 peptides. "Peptide immunogens used as a component of a vaccine ... In addition, vaccine developers have been criticized for aggressively advertising their vaccine efficacy prior to the ...
"Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and ... In 1997, nasal-spray vaccine containing inactivated influenza virus with nLT (heat-labile enterotoxin) as adjuvants was used in ...
Bernstein, Alan (1972). A Genetic Analysis of the TOL(A,B) Locus of Escherichia Coli K-12 (PhD thesis). University of Toronto. ... In 2007, he became the first executive director of the Global HIV Vaccine Enterprise, an alliance of independent organizations ... in 1972 under the supervision of James Till with a thesis focusing on a genetic analysis of membrane mutants Escherichia coli. ... Berkley, Seth (September 2010). "The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise". Nature Medicine. 16 ...
Norton, E. B.; Lawson, L. B.; Mahdi, Z.; Freytag, L. C.; Clements, J. D. (23 April 2012). "The A Subunit of Escherichia coli ... In addition to some of these AB5 toxins being used to create vaccines to prevent bacterial infection, they are also being ... Shiga toxin, also known as Stx, is a toxin that is produced by the rod shaped Shigella dysenteriae and Escherichia coli (STEC ... Weltzin, R; Guy, B; Thomas WD, Jr; Giannasca, PJ; Monath, TP (May 2000). "Parenteral adjuvant activities of Escherichia coli ...
A vaccine in which the beta subunit of hCG is fused to the B subunit of Escherichia coli heat-labile enterotoxin has been ... for the development of contraceptive vaccine for male". Vaccine. 26 (29-30): 3711-3718. doi:10.1016/j.vaccine.2008.04.060. PMID ... Repro-Bloc is GnRH vaccine marketed for use in domestic animals in general. Improvac® is a GnRH vaccine marketed for use in ... "Repro-Bloc Vaccine Technology". Amplicon Vaccine, LLC. Archived from the original on 2012-10-18. Retrieved 2 June 2012. " ...
"Construction of a recombinant-attenuated Salmonella Enteritidis strain secreting Escherichia coli heat-labile enterotoxin B ... doi:10.1016/j.vaccine.2013.10.054. PMID 24176491. Neuman, William (2010-08-24). "U.S. Forgoes Salmonella Vaccine for Egg Safety ... This could lead to a possible Salmonella vaccine for humans. A 2014 study tested a vaccine on chickens which offered efficient ... The country eradicated salmonella without vaccines and antibiotics by focusing on eliminating the infection from "breeder ...
Risk of Transmission of Antimicrobial Resistant Escherichia coli from Commercial Broiler and Free-Range Retail Chicken in India ... Vaccine, 27, 2804-2811. 120. Marathe S, Negi VD, Chakravortty D,2009, Curcumin! Spicy panacea for all-- friend or foe. Vaccine ... Lahiri A, Da, P, Chakravortty D,2008,Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine, 26, ... Non-neutral evolution in non-LEE-encoded type III effectors of attaching and effacing Escherichia coli., Microbes Infect., ...
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of ... Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract ...
... of Campylobacter jejuni in recombinant Escherichia coli has been suggested as a simpler method for producing conjugate vaccines ... suggesting that glycosylation was the rate-limiting step for synthesis of conjugate vaccines in E. coli. Glycoconjugate ... State-of-the art production of conjugate vaccines using chemical methods is a laborious, multi-step process. In vivo enzymatic ... In this study we describe the in vivo biosynthesis of two novel conjugate vaccine candidates against Shigella dysenteriae type ...
Enteroinvasive E coli, based on the sero-logic, genetic, and pathogenic similarities with Shigella ... Vaccines. Class Summary. These agents elicit active immunization to increase resistance to infection. Vaccines consist of ... A review of vaccine research and development: human enteric infections. Vaccine. 2006 Apr 5. 24(15):2732-50. [QxMD MEDLINE Link ... Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database of Systematic Reviews. 2012. ...
No vaccine is available for E. coli infection. Although bismuth subsalicylate and certain antimicrobial agents (e.g., ... Abbreviations: DAEC, diffusely adherent Escherichia coli; EAEC, enteroaggregative E. coli; EIEC, enteroinvasive E. coli; EPEC, ... coli (EPEC), enteroaggregative E. coli (EAEC), and enteroinvasive E. coli (EIEC). In addition, diffusely adherent E. coli (DAEC ... Escherichia coli, Diarrheagenic. CDC Yellow Book 2024. Travel-Associated Infections & Diseases Author(s): Jennifer Collins, ...
Categories: Escherichia coli Vaccines Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, ...
Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: ... Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohns disease. Gastroenterology 1995 ... vaccine, Haemophilus influenzae type b (Hib) vaccine, and oral poliovirus vaccine (OPV) or inactivated poliovirus vaccine (IPV ... Reconstituted vaccine must be discarded if not used within 8 hours.. VACCINE USAGE Two doses of MMR vaccine separated by at ...
... in saliva and intestinal secretions and by challenge with virulent enterotoxigenic Escherichia coli (ETEC). A combination of ... are encouraging and demonstrate that it may be possible to develop an effective oral vaccine based on soluble nonreplicating ... of enterotoxigenic Escherichia coli to volunteers. Response to challenge with virulent enterotoxigenic Escherichia coli ... in saliva and intestinal secretions and by challenge with virulent enterotoxigenic Escherichia coli (ETEC). A combination of ...
Research progress of enterotoxigenic Escherichia coli vaccine for piglets. Enterotoxigenic Escherichia coli (ETEC) is an ... mRNA vaccines have achieved results in the treatment of tumours and the prevention of infectious diseases. Compared with ... This study presents the results of a survey of the safety and protective efficacy of a candidate vector-based vaccine for ... Research progress of porcine epidemic diarrhea vaccine for pigs. Porcine epidemic diarrhea (PED) caused by porcine epidemic ...
Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference. Vaccine. 2017 Dec 14;35( ... Vaccines against Shigella and enterotoxigenic Escherichia coli : A summary of the 2016 VASE Conference. In: Vaccine. 2017 ; Vol ... Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference. Vaccine, 35(49), 6775- ... Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference, Vaccine, vol. 35, no. ...
"Status of vaccine research and development for enterotoxigenic Escherichia coli". Vaccine. 34 (26): 2880-86. doi:10.1016/j. ... Wikispecies has information related to Escherichia coli. Wikimedia Commons has media related to Escherichia coli. EcoCyc - ... coli K-12. Uropathogenic Escherichia coli (UPEC) AlignACE Matrices that search for additional binding sites in the E. coli ... coli helped produce E. coli O157:H7, the Shiga toxin-producing strain of E. coli. E. coli encompasses an enormous population of ...
Expression System: Escherichia coli. *Mutation(s): No *Deposited: 2015-02-25 Released: 2015-03-11 ... The Plasmodium vivax vaccine candidate Duffy Binding Protein (DBP) is a protein necessary for P. vivax invasion of ... DEKnull is an iterative improvement of DBP as a vaccine candidate. DEKnull has reduced immunogenicity to polymorphic regions ... Structural Analysis of the Synthetic Duffy Binding Protein (DBP) Antigen DEKnull Relevant for Plasmodium vivax Malaria Vaccine ...
"Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea". The Cochrane Database of Systematic Reviews. 7 (7 ... The bacteria enterotoxigenic Escherichia coli (ETEC) are typically the most common except in Southeast Asia, where ... The most common causative agent isolated in countries surveyed has been enterotoxigenic Escherichia coli (ETEC).[11] ... Enterotoxigenic Escherichia coli (ETEC). Archived 2012-05-15 at the Wayback Machine ...
New sections on infectious diseases related to travel: Escherichia coli, Salmonellosis, Fascioliasis, and Hand, Foot, and Mouth ... It includes a complete catalog of travel-related diseases and up-to-date vaccine and booster recommendations. The information ... An expanded destination-specific list of vaccine requirements and recommendations to help travelers prepare for their next trip ...
Influenza Surveillance Trends and Influenza Vaccine Effectiveness Among Department of Defense Beneficiaries During the 2019- ... Case Report: Complicated Urinary Tract Infection Due to an Extensively Resistant Escherichia coli in a Returning Traveler. ... Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017-2018 influenza season. Vaccine. ... Updated COVID-19 vaccines are now available for people ages 6 months and older. Heres how to get the updated vaccine at no ...
There is a religious exemption possibility for any mandatory vaccine, and theres a process that we go through to counsel the ... Case Report: Complicated Urinary Tract Infection Due to an Extensively Resistant Escherichia coli in a Returning Traveler. ... The Johnson & Johnson vaccine requires only a single shot.. If any of the three vaccines receive full licensure by the FDA ... prepare syringes with doses of the Pfizer COVID-19 vaccine during a vaccine distribution event at Commander, Fleet Activities ...
Influenza Surveillance Trends and Influenza Vaccine Effectiveness Among Department of Defense Beneficiaries During the 2019- ... Case Report: Complicated Urinary Tract Infection Due to an Extensively Resistant Escherichia coli in a Returning Traveler. ... Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017-2018 influenza season. Vaccine. ... To improve vaccine effectiveness (VE) against influenza viruses, the strains used in the influenza vaccine need to be updated ...
First described in 1885, E coli has become recognized as both a harmless commensal and a versatile pathogen. ... Escherichia coli, a facultatively anaerobic gram-negative bacillus, is a major component of the normal intestinal flora and is ... Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children. J ... encoded search term (Pediatric Escherichia Coli Infections) and Pediatric Escherichia Coli Infections What to Read Next on ...
The estimated effect of cholera, shigella, Enterotoxigenic Escherichia coli (ETEC) and rotavirus vaccines was determined by ... But there is no substantial evidence of efficacy for ETEC and shigella vaccines, although several promising vaccine concepts ... A total of 24 papers were selected and analyzed for all the four vaccines. Based on the evidence, we propose a 74% mortality ... Vaccines for rotavirus and cholera have the potential to reduce diarrhea morbidity and mortality burden. ...
O-Antigen Targeted Vaccines Against Escherichia coli May Be Useful in Reducing Morbidity, Mortality, and Antimicrobial ... Activating Silent Glycolysis Bypasses in ,i,Escherichia coli,/i,. Iacometti C, Marx K, H"nick M, Biletskaia V, Schulz-Mirbach H ... The Population Genomics of Increased Virulence and Antibiotic Resistance in Human Commensal Escherichia coli over 30 Years in ... Genetic and biocatalytic basis of formate dependent growth of Escherichia coli strains evolved in continuous culture. ...
Experimental vaccination with nanoparticles containing Escherichia coli virulence factors 2. Vaccine as immunotherapy for ... leishmaniasis 3. Polymeric particles as a delivery agent for malarial vaccines. Part II: Nano-Diagnostics and Detection of NTD ...
Vaccination of Chickens with Lipsomal Inactivated Avian Pathogenic Escherichia coli Vaccine by Eye Drop or Coarse Spray ... Pap Mutant of Avian Pathogenic Escherichia coli O1, an O1:K1:H7 Strain, is Attenuated in vivo ... Efficacy of a Novel Trivalent Inactivated Vaccine against the Shedding of Salmonella in a Chicken Challenge Model ... Vaccination with Newcastle Disease Virus Vectored Vaccine Protects Chickens Against Highly Pathogenic H7 Avian Influenza Virus ...
Subjects with known hypersensitivity to Escherichia coli (E. coli)-derived proteins (only applicable for subjects getting ... Use of any live vaccines against infectious diseases within 8 weeks before JCARH125 infusion. ...
A Survey of Escherichia coli O157:H7 Virulence Factors: The First 25 Years and 13 Genomes (Articles) ... This article belongs to the Special Issue on Veterinary Vaccines and Immunology ...
... of a pilin subunit BfpA of the bundle-forming pilus of enteropathogenic Escherichia coli in an aroA live salmonella vaccine ...
Factors affecting cattle producers willingness to adopt an Escherichia coli O157:H7 vaccine: a probit analysis International ... Incentives for cattle producers to adopt an E. Coli vaccine: An application of best-worst scaling Food Policy, 2016, 59, (C), ...
... including Escherichia coli and other gram-negative pathogens) should take into account local antibiotic resistance patterns. ...
Humoral Immune Response of Immunized Sows with Recombinant Proteins of Enterotoxigenic Escherichia coli, World Journal of ... Introduction of Inactivated Polio Vaccine and Specific Determinants of Vaccine Hesitancy, World Journal of Vaccines, Vol.5 No.1 ... HER2-Specific Vaccines for HER2-Positive Breast Cancer Immunotherapy, World Journal of Vaccines, Vol.5 No.2, 2015 ... Universal COVID-19 Vaccine Targeting SARS-CoV-2 Envelope Protein, World Journal of Vaccines, Vol.11 No.3, 2021 ...
... and that certain natural compounds kill foodborne pathogens like Salmonella or Escherichia coli O157:H7. Other research ... breakthroughs include creating new, effective antimicrobials and vaccines to fight such pathogens as Salmonella and ...
Comparative Pathogenomics of Escherichia coli: Polyvalent Vaccine Target Identification through Virulome Analysis. Clark, J R; ... Surviving Serum: the Escherichia coli iss Gene of Extraintestinal Pathogenic E. coli Is Required for the Synthesis of Group 4 ... Home > Pesquisa > mh:Escherichia coli Extraintestinal Patogênica (183) Busca. Selecione o campo de pesquisa. Título, resumo, ... Broad protective vaccination against systemic Escherichia coli with autotransporter antigens. Xing, Yikun; Clark, Justin R; ...
... coli O157 shedding, a vaccine may be a better method to stave off the bacteria. ... Use of a siderophore receptor and porin proteins-based vaccine to control the burden of Escherichia coli O157:H7 in feedlot ... Use of a Siderophore Receptor and Porin Proteins-Based Vaccine to Control the Burden of Escherichia coli O157:H7 in Feedlot ... Top): The E. coli vaccine with SRP technology reduced the number of cattle testing positive for E. coli by 85 percent. (Bottom ...

No FAQ available that match "escherichia coli vaccines"